Urinary Gonadotropin Peptide in Bladder Cancer Patients
Author Information
Author(s): 0 El-Ahmady, A-B Halim, O Mansour, T Salman, A Gamal El-Din, RP Walker
Primary Institution: Tumor Marker Oncology Research Center, Al-Azhar University, Cairo, Egypt
Hypothesis
The study aims to evaluate the expression of urinary gonadotropin peptide (UGP) in patients with invasive bladder cancer compared to those with benign urological disease and normal individuals.
Conclusion
UGP levels are significantly higher in bladder cancer patients compared to those with benign disease and normal individuals, suggesting its potential as a marker for malignancy.
Supporting Evidence
- The mean UGP level in bladder cancer patients was 4.86 fmol ml-1, significantly higher than 0.06 fmol ml-1 in normal subjects and 0.11 fmol ml-1 in benign disease patients.
- At 95% specificity, the sensitivity of UGP for detecting bladder cancer was 73%.
- UGP levels were significantly correlated with the stage and grade of malignant disease.
Takeaway
This study found that a substance called UGP is much higher in the urine of people with bladder cancer than in those without cancer, which could help doctors tell the difference between cancer and non-cancer cases.
Methodology
The study measured UGP levels in urine samples from 450 individuals, including patients with bladder cancer, benign urological disease, and normal controls, using an enzyme-linked immunoassay.
Limitations
The study primarily involved male participants, which may affect the generalizability of the results.
Participant Demographics
The study included 237 bladder cancer patients (171 males, 66 females), 97 patients with benign urinary tract disease (90 males, 7 females), and 116 normal controls (107 males, 9 females).
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website